Book Chapters

Giles FJ, Durie BGM (1993) 'Multiple Myeloma' In: Therapies and Strategies in Oncology. Heidelberg: Springer Verlag. [Details]

Giles FJ, HH Timmis, Jr. (1994) 'Hodgkin's Disease and the Non-Hodgkin's Lymphomas: Diagnosis, Staging and Therapy' In: The Neck: Diagnosis and Surgery. St. Louis: Mosby-Year Book Inc. [Details]

Giles FJ, Durie BGM (1994) 'Myelomatosis' In: Postgraduate Hematology IVth Ed. London: Butterworth-Heinmann. [Details]

Giles FJ (1995) 'Multiple Myeloma (Plasmozytom)' In: Therapies and Strategies in Oncology IInd Ed. Heidelberg: Springer Verlag. [Details]

Giles FJ (1995) 'Multiple myeloma and other differentiated B-cell disorders' In: Current Review of Hematology. Philadelphia: Churchill Livingstone. [Details]

Giles FJ (1995) 'Secondary myelodysplastic syndromes and leukemias' In: Current Review of Hematology. Philadelphia: Churchill Livingstone. [Details]

Giles FJ (1995) 'Multiple myeloma and Waldenstroms Macroglobulinemia' In: Current Therapy in Hematology Oncology Vth Ed. Philadelphia: Mosby-Year Book. [Details]

Giles FJ, Koeffler HP (1995) 'Cytogenetics and molecular biology of acute myeloid leukemias' In: Cancer Treatment IVth Edition. Philadelphia: W.B. Saunders. [Details]

Giles FJ, Koeffler HP (1995) 'Chronic myelogenous leukemia' In: Cancer Treatment IVth Edition. Philadelphia: W.B. Saunders. [Details]

Giles FJ (1996) 'Treatment of refractory multiple myeloma with cytotoxic therapy and Radiation therapy' In: Multiple Myeloma. New York: Edward Arnold. [Details]

Giles FJ, Lim SW (1996) 'Malignant splenic lesions' In: Surgical Diseases of the Spleen. New York: Springer-Verlag. [Details]

Durie BGM, Giles FJ (1996) 'Myeloma and other paraproteinemias' In: Oxford Textbook Of Medicine IIIrd Ed. Oxford: Oxford University Press. [Details]

Giles FJ (1996) 'Multiple myeloma and Waldenstroms Macroglobulinemia' In: Current Therapy in Internal Medicine IVth Ed. Philadelphia: Mosby-Year Book. [Details]

Giles FJ (1997) 'Multiple myeloma and Waldenstroms Macroglobulinemia' In: Current Therapy in Adult Medicine. Philadelphia: Mosby-Year Book. [Details]

Giles FJ (1997) 'Treatment of multiple myeloma' In: Medical Management of Hematologic Malignant Disease. New York: Marcel Dekker. [Details]

Giles FJ (1997) 'Multiple Myeloma (Plasmozytom)' In: Therapies and Strategies in Oncology IIIrd Ed. Heidelberg: Springer Verlag. [Details]

Giles FJ, Durie BGM (1998) 'Myelomatosis ( in multiple myeloma)' In: Postgraduate Haematology IVth Ed. London: Butterworth-Heinmann. [Details]

Giles, FJ, HM Kantarjian (1999) 'Therapy of Chronic Myelogenous Leukemia' In: Oncologic Therapies. Heidelberg: Springer Verlag. [Details]

Giles FJ (2000) 'Multiple Myeloma (Plasmozytom)' In: Therapies and Strategies in Oncology IVth Ed. Heidelberg: Springer Verlag. [Details]

Giles FJ, Keating M, Andreeff M (2000) 'Therapy of the acute myeloid leukemias' In: Cancer Treatment Vth Edition. Philadelphia: W.B. Saunders. [Details]

Mattiuzzi G, Alvarez RH, Giles F (2003) 'Treatment of invasive Aspergillus infections in BMT patients' In: Antibiotics for Clinicians, Supplement 1: Fungal Infections in Hospitalized Patients. N/A: AFC Volume 7. [Details]

Ravandi F, Giles F (2007) 'Approaching the Treatment of AML from a biological perspective: An overview' In: Acute Myelogenous Leukemia. New Jersey: Humana Press. [Details]

Yee K, Giles FJ (2007) 'Antiangiogenic Therapy for Hematologic Malignancies' In: Antiangiogenic Cancer Therapy. N/A: Catalog 2799. [Details]

 

Peer Reviewed Journals

Swords, R,Apostolidou, E,Giles, F (2006) 'Troxacitabine in leukemia'. Hematology, 11 :321-329. [DOI] [Details]

Swords, R,Giles, F (2007) 'Troxacitabine in acute leukemia'. Hematology, 12 :219-227. [DOI] [Details]

Swords, R,Alvarado, Y,Giles, F (2007) 'Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia'. Clinical Lymphoma & Myeloma, 7 :113-119. [Details]

Swords R, Mahalingam D, O'Dwyer M, Santocanale C, Kelly K, Carew J, Giles F (2010) 'Cdc7 kinase - a new target for drug development'. European Journal Of Cancer, 46 (1):33-40. [DOI] [Details]

Swords, RT,Kelly, KR,Smith, PG,Garnsey, JJ,Mahalingam, D,Medina, E,Oberheu, K,Padmanabhan, S,O'Dwyer, M,Nawrocki, ST,Giles, FJ,Carew, JS (2010) 'Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia'. Blood, 115 :3796-3800. [DOI] [Details]

Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, Oberheu K,Padmanabhan S, O'Dwyer M, Nawrocki ST, Giles FJ, Carew JS (2010) 'Inhibition of EDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia'. Blood, 115 (18):3796-3800. [DOI] [Details]

Cronin CG, Swords R, Truong MT, Viswanathan C, Rohren E, Giles FJ, O'Dwyer M, (2010) 'Bruzzi JF. Clinical utility of PET/CT in lymphoma. AJR Am J Roentgenol. 2010'. Review, 191 (1):W91-W103. [DOI] [Details]

Swords R, Mahalingam D, O'Dwyer M, Santocanale C, Kelly K, Carew J, Giles F. (2010) 'Cdc7 kinase - a new target for drug development'. Eur J Cancer, 46 (1):33-40. [Details]

Mahalingam D, Espitia CM, Medina EC, Esquivel JA 2nd, Kelly KR, Bearss D, Choy G, Taverna P, Carew JS, Giles FJ, Nawrocki ST (2011) 'Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma'. Br J Cancer, 105 (10):1563-1573. [DOI] [Details]

Swords RT, Anguita J, Higgins RA, Yunes AC, Naski M, Padmanabhan S, Kelly KR, Mahalingam D, Philbeck T, Miller L, Puga TA, Giles FJ, Kinney MC, Brenner AJ (2011) 'A prospective randomised study of a rotary powered device (OnControl) for bone marrow aspiration and biopsy'. Journal Of Clinical Pathology, 64 (9):809-813. [DOI] [Details]

le Coutre, P.D., Giles, F.J., Hochhaus, A., Apperley, J.F., Ossenkoppele, G.J., Blakesley, R., Shou, Y., Gallagher, N.J., Baccarani, M., Cortes, J., Kantarjian, H.M. (2011) 'Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results'. Leukemia, . [Details]

Burke, A.C., Giles, F.J. (2011) 'Elacytarabine lipid vector technology overcoming drug resistance in acute myeloid leukemia'. Expert Opinion on Investigational Drugs, 20 (12):1707-1715. [Details]

Giles, F.J., Kantarjian, H.M., le Coutre, P.D., Baccarani, M., Mahon, F.-X., Blakesley, R.E., Gallagher, N.J., Gillis, K., Goldberg, S.L., Larson, R.A., Hochhaus, A., Ottmann, O.G. (2011) 'Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase'. Leukemia, . [Details]

Burke, AC,Giles, FJ (2011) 'Elacytarabine - lipid vector technology overcoming drug resistance in acute myeloid leukemia'. Expert Opinion On Investigational Drugs, 20 :1707-1715. [DOI] [Details]

Cortes, JE,Hochhaus, A,le Coutre, PD,Rosti, G,Pinilla-Ibarz, J,Jabbour, E,Gillis, K,Woodman, RC,Blakesley, RE,Giles, FJ,Kantarjian, HM,Baccarani, M (2011) 'Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib'. Blood, 117 :5600-5606. [DOI] [Details]

Kim, TD,le Coutre, P,Schwarz, M,Grille, P,Levitin, M,Fateh-Moghadam, S,Giles, FJ,Dorken, B,Haverkamp, W,Kohncke, C (2012) 'Clinical cardiac safety profile of nilotinib'. Haematologica-The Hematology Journal, 97 :883-889. [DOI] [Details]

Carew JS, Esquivel JA 2nd, Espitia CM, Schultes CM, Mülbaier M, Lewis JD, Janssen B, Giles FJ, Nawrocki ST (2012) 'ELR510444 Inhibits Tumor Growth and Angiogenesis by Abrogating HIF Activity and Disrupting Microtubules in Renal Cell Carcinoma'. Plos One, 7 (1). [DOI] [Details]

O'Brien, S,Rizzieri, DA,Vey, N,Ravandi, F,Krug, UO,Sekeres, MA,Dennis, M,Venditti, A,Berry, DA,Jacobsen, TF,Staudacher, K,Bergeland, T,Giles, FJ (2012) 'Elacytarabine has single-agent activity in patients ?with advanced acute myeloid leukaemia'. British Journal Of Haematology, 158 :581-588. [DOI] [Details]

Stone, RM,Fischer, T,Paquette, R,Schiller, G,Schiffer, CA,Ehninger, G,Cortes, J,Kantarjian, HM,DeAngelo, DJ,Huntsman-Labed, A,Dutreix, C,del Corral, A,Giles, F (2012) 'Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 26 :2061-2068. [DOI] [Details]

Yin, OQP,Giles, FJ,Baccarani, M,le Coutre, P,Chiparus, O,Gallagher, N,Saglio, G,Hughes, TP,Hochhaus, A,Kantarjian, HM,Larson, RA (2012) 'Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia'. Cancer Chemotherapy And Pharmacology, 70 :345-350. [DOI] [Details]

le Coutre, PD,Giles, FJ,Hochhaus, A,Apperley, JF,Ossenkoppele, GJ,Blakesley, R,Shou, Y,Gallagher, NJ,Baccarani, M,Cortes, J,Kantarjian, HM (2012) 'Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 26 :1189-1194. [DOI] [Details]

Giles, FJ,Kantarjian, HM,le Coutre, PD,Baccarani, M,Mahon, FX,Blakesley, RE,Gallagher, NJ,Gillis, K,Goldberg, SL,Larson, RA,Hochhaus, A,Ottmann, OG (2012) 'Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 26 :959-962. [DOI] [Details]

Bansal, H., Bansal, S., Rao, M., Ying, W., Sang, J., Kelly, K., Swords, R.P., Foley, K.P., Barsoum, J., Repasky, E., Giles, F.J., Lee, K.P., Padmanabhan, S.. (2010) 'Heat Shock Protein 90 regulates the expression of Wilm’s tumor 1 protein in myeloid leukemias'. Blood, 116 :4591-4599. [Details]

Prajapati, S.I., Kilcoyne, A., Samano, A.K., Green, D.P., McCarthy, S.D., Blackman, B.A., Brady, M.M., Zarzabal, L.A., Tatiparthy, A.K., Sledz, T.J., Duong, T., Ohshima-Hosoyama, S., Giles, F.J., Michalek, J.E., Rubin, B.P., Keller, C. (2010) 'MicroCT-based virtual histology evaluation of preclinical medulloblastoma'. Molecular Imaging Biology, . [Details]

Carew, J.S., Esquivel, J.A., Mahalingam, M., Olaya, C.M., Swords, R., Kelly, K., Giles, F.J.,  Nawrocki, S.T. (2010) 'Lucanthone: A novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis'. Journal of Biological Chemistry, . [Details]

Fisher. T., Stone, R.M., DeAngelo, D., Galinsky, I., Estey, E., Cohen, P., Fox, E., Ehninger, G., Feldman, E.J.,  Schiller, G.J., Klimek, V.M., Nimer, S.D., Gilliland, D.G., Wong, Y.F., Massimini, G., Giles, F.J. (2010) 'A Phase IIB trial of the putative FLT3 and mutlitargeted kinase inhibitor PKC412 (N-benzoylstaurosporine; Midostaurin) in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome with either wild-type or mutated FLT3'. Journal of Clinical Oncology, 28 :4339-4345. [Details]

Kelly, K., Swords, R., Mahalingam, D., Giles, F. (2010) 'Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents'. Leukemia Lymphoma, 51 :1399-1413. [Details]

Kelly, K., Swords, R., Mahalingam, D., Nawrocki, S., Padmanabhan, S., Giles, F., Carew, S (2010) 'The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukemia and significantly increases the efficacy of nilotinib'. Journal of Cellular and Molecular Medicine, . [Details]

Kantarjian, H.M., Giles, F.J., Greenberg, P.L., Paquette, R.L., Wang, E.S., Gabrilove, J.L., Garcia-Manero, G., Hu, K., Franklin, J.L., Berger, D.P (2010) 'Phase II study of romiplostim in patients with low- or Intermediate-risk myelodysplastic syndrome receiving azacitidine therapy'. Blood, 116 :3163-3170. [Details]

Kantarjian, H.M., Giles, F.J., Bhalla, K.P., Pinilla, J., Larson, R.A., Gattermann, N., Ottmann, O., Hochhaus, A., Radich, J.P., Saglio, G., Hughes, T.P., Martinelli, G., Kim, D.W., Shou, Y., Gallagher, N.J., Blakesley, R., Baccarani, M., Cortes, J., le Coutre, P.D. (2010) 'Nilotinib, a potent and selective BCR-ABL inhibitor, is effective in patients with chronic myeloid leukemia in chronic phase following imatinib resistance or intolerance: 24-month follow-up results of a phase 2 study'. Blood, . [Details]

Ma, W., Giles, F., Zhang, X., Wang, X., Zhang, Z., Lee, T.S., Yeh, C.H., Albitar, M (2011) 'Three novel alternative splicing mutations in BCR-ABL1 detected in CML patients with resistance to kinase inhibitors'. International Journal Laboratory Hematology, . [Details]

Lapusan, S., Vidriales, M.B., Thomas, X., de Botton, S., Vekhoff, A., Tang, R., Dumontet, C.,    Morariu-Zamfir, R., Lambert, J.M., Ozoux, M.L., Poncelet, P., San Miguel, J.F ., Legrand, O., De Angelo, D., Giles, F.J. , Marie, J.P (2011) 'Dose-escalation phase I studies of AVE9633, an anti CD33 antibody- maytansinoid conjugate, administered as a single agent by intravenous infusion to adult patients with relapsed or refractory CD33-positive acute myeloid leukemia'. Investigational New Drugs, . [Details]

Burke, A.C., Swords, R.T., Kelly, K., Giles, F.J. (2011) 'Current status of agents active against the T315I chronic myeloid leukemia phenotype'. Expert Opinion on Emerging Drugs, 16 (1):85-103. [Details]

Qu, K.Z., Zhang, K., Ma, W., Li, H., Wang, X., Zhang, X., Giles, F., Lai, M., Afdhal, N.H., Albitar, M. (2011) 'Ubiquitin-Proteasome signature for detection of hepatocellular carcinoma'. Journal Gastroenterology and Hepatology, 26 :751-758. [Details]

 

Conference Publications

Burke, AJ; O'Connell, E; Miranda, KM; Giles, FJ; Sullivan, F; Glynn, SA (2012) Nitric Oxide and its effects on cellular proliferation and phenotype in prostate cancer Royal Academy of Medicine in Ireland Annual Meeting NUI Galway, Ireland, [Details]

 

Abstract

Swords, RT,Kelly, KR,Smith, PG,Gansey, JJ,Mahalingam, D,Padmanabhan, S,O'Dwyer, MC,Nawrocki, ST,Giles, FJ,Carew, JS (2009) MLN4924, A Novel First in Class Small Molecule Inhibitor of the Nedd8 Activating Enzyme (NAE), Has Potent Activity in Preclinical Models of Acute Myeloid Leukemia. Abstract [Details]

O'Dwyer, MC,Kent, E,Parker, M,Swords, RT,Giles, F,le Coutre, P,Padmanabhan, S,Moulton, B,McMullin, MF,Langabeer, S,Egan, K,Conneally, E (2009) Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study. Abstract [Details]

O'Dwyer, E,Swords, R,Giles, F,LeCoutre, P,McMullin, M,Langabeer, S,Padmanabhan, S,Kent, E,Parker, M,Moulton, B,Egan, K,Conneally, E (2010) NILOTINIB 300 MG TWICE DAILY IS EFFECTIVE AND WELL TOLERATED AS FIRST LINE TREATMENT OF PH-POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: UPDATED RESULTS OF THE ICORG 0802 PHASE 2 STUDY. Abstract [Details]

                                                                                                     

Reviews

Swords, R,Bruzzi, J,Giles, F (2007) Recent advances in the diagnosis and therapy of Richter's syndrome. Reviews [Details]

Swords, R,Giles, F (2007) Hairy cell leukemia. Reviews [Details]

Apostolidou, E,Swords, R,Alvarado, Y,Giles, FJ (2007) Treatment of acute lymphoblastic leukaemia - A new era. Reviews [Details]

Giles, FJ,O'Dwyer, M,Swords, R (2009) Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Reviews [DOI] [Details]

Giles, FJ,Rosti, G,Beris, P,Clark, RE,le Coutre, P,Mahon, FX,Steegmann, JL,Valent, P,Saglio, G (2010) Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. Reviews [DOI] [Details]

Cronin, CG,Swords, R,Truong, MT,Viswanathan, C,Rohren, E,Giles, FJ,O'Dwyer, M,Bruzzi, JF (2010) Clinical Utility of PET/CT in Lymphoma. Reviews [DOI] [Details]

Swords, R,Mahalingam, D,O'Dwyer, M,Santocanale, C,Kelly, K,Carew, J,Giles, F (2010) Cdc7 kinase - A new target for drug development. Reviews [DOI] [Details]

Mahalingam, D,Oldenhuis, CNAM,Szegezdi, E,Giles, FJ,de Vries, EGE,de Jong, S,Nawrocki, ST (2011) Targeting Trail Towards the Clinic. Reviews [Details]

Wang, M,Medeiros, BC,Erba, HP,DeAngelo, DJ,Giles, FJ,Swords, RT (2011) Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer. Reviews [DOI] [Details]

Burke, AC,Swords, RT,Kelly, K,Giles, FJ (2011) Current status of agents active against the T315I chronic myeloid leukemia phenotype. Reviews [DOI] [Details]

Giles, F,Mahon, FX,Gjertsen, B,Swords, R,Labar, B,Turkina, A,Rosti, G (2012) Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia. Reviews [DOI] [Details]

Keane, N,Freeman, C,Swords, R,Giles, FJ (2012) EPHA3 as a novel therapeutic target in the hematological malignancies. Reviews [DOI] [Details]

Freeman, CL,Swords, R,Giles, FJ (2012) Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?. Reviews [DOI] [Details]

Alvarado, Y,Giles, FJ,Swords, RT (2012) The PIM kinases in hematological cancers. Reviews [DOI] [Details]